Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedosiran (DCR-PHXC) in Healthy Volunteers and Primary Hyperoxaluria Patients
NCT03392896Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2017
- Primary completion
- Nov 2019
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of nedosiran in Primary hyperoxaluria (PH) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment-Emergent Adverse Events at Day 57. Started Dec 2017; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NCT03392896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392896.